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Abstract
In brain, the tryptophan degradation products through the kynurenine pathway exhibit 
neuromodulatory and inflammatory effects and have been related to the progression 
of neurodegenerative disorders, furthermore, their protagonism on the modulation 
of immune response and in cancer development has been reported. The immunosup‐
pressive role of kynurenines has been described on glioblastoma models. In patients, 
the elevated activity of indoleamine-2,3-dioxygenase (IDO) such as the increase of kyn‐
urenine/tryptophan ratio have been also reported, suggesting that activation of kynuren‐
ine pathway is present during glioblastoma formation and can be related with tumor 
progression. The importance of the kynurenine pathway during cancer development 
has encouraged recent studies to the use of IDO inhibitors as a therapeutic strategy for 
treatment of breast, lung and ovarian cancer, until to get its use in clinical trials. IDO 
inhibitors also have been used in in vitro and in vivo models of glioblastoma showing 
promising results. The effect of kynurenines on glioblastoma offer a new perspective 
about the tryptophan metabolism during cancer. Due to the relevance of the kynurenine 
pathway in brain homeostasis, immunomodulation and cancer, we discuss the relevance 
of the kynurenine pathway on the development of glioblastoma multiforme as well as a 
possible molecular target for glioblastoma treatment.
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1. Introduction
Tryptophan (Trp) is considered as an essential amino acid, which is required for life and 
growth but is not synthesized by the organism. Although approximately 1% of trypto‐
phan dietary intake is used for protein synthesis, the rest 99% is metabolized through the 
5‐hydroxyindole pathway for the production of melatonin and serotonin, decarboxylated to 
tryptamine, transaminated to indol-3-pyruvic acid, or oxidized by the so-named kynurenine 
pathway (KP), for the new synthesis of NAD+ and NADP+ (Figure 1) [1–3].
The KP degrades over 95% of whole tryptophan intake; its rate-limiting enzymes, tryptophan 
2,3-dioxygenase (TDO), and indoleamine 2,3-dioxygenase (IDO), catalyze the cleavage of the 
tryptophan pyrrole ring to produce N-formylkynurenine [1, 4]. Among mammals, TDO is 
mainly expressed in liver and only uses l-tryptophan as a specific substrate; instead of that, 
IDO is expressed in extrahepatic tissues, such as brain, lung, kidney, and immune cells [1, 
4]. Furthermore, IDO’s substrate span is wider than TDO’s, being d‐ or l‐tryptophan, d‐ or 
l-hydroxytryptophan, tryptamine, serotonin, and melatonine available for the catalytic activ‐
ity of IDO [5]. An IDO isoenzyme has been reported, IDO2 is expressed in the murine kid‐
ney, liver, and reproductive system, and the gene encoding IDO2 is adjacent to the IDO gene 
and has similar affinity for substrates than IDO [6, 7]. N-formylkynurenine is transformed 
Figure 1. Tryptophan catabolism occurs by different pathways. Ninety-five percent of the dietary uptake of tryptophan 
is catabolized mainly by the kynurenine pathway. About 3% is decarboxylated to tryptamine or transaminated to 
indol-3-pyruvic acid, 1% is intended for serotonin and melatonin synthesis, and resting 1% is for protein synthesis.
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Figure 2. The kynurenine pathway.
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to l-kynurenine (l-kyn) by the arylformidase (AFMID); kynurenine aminotransferases (KAT 
I, KAT II), and kynureninase (KYNU), with pyridoxal-5′-phosphate as a cofactor, as well as 
kynurenine monooxygenase (KMO), which uses FAD as a cofactor, transform l‐kyn into 
kynurenic acid (Kyna), anthranilic acid (AA), or 3-hydroxykynurenine (3-HK), respectively 
[8–10]. KMO is located in mitochondrial outer membrane and it has been shown to have high 
affinity by the substrate suggesting that KMO metabolizes more l‐kyn than other enzymes 
[11]. KATs and KYNU can also use 3-HK as a substrate to produce xanthurenic acid (Xanth) 
or 3-hydroxyanthranilic acid (3HAA) [8, 12]. Oxidation of 3HAA by the 3HAA dioxygen‐
ase (3HAADO) produces 2-amino-3-carboxymuconate semialdehyde (Acms) which is trans‐
formed by non-enzymatic dehydration into quinolinic acid (Quin), or into picolinic acid (Pic) 
by the Acms decarboxylase (ACMSD). Finally, Quin phosphoribosyltransferase (QPRT) uses 
Quin as a substrate for the formation of nicotinamine-adenine-mononucleotide (NaMN), the 
nicotinamine-adenine-dinucleotide (NAD+) precursor (Figure 2) [13, 14]. Enzyme kinetics of 
the whole KP have been determined, giving a wide perspective of the kynurenine pathway 
and its functionality [13], enzyme kinetics data of the KP are summarized in Table 1.
Enzyme Substrate K
M
 (mM) K
cat
 (s−1) Reference
IDO 5-Hydroxytriptamine 0.02 0.043 [5, 13, 15]
Serotonin 0.1 0.002
Tryptophan 0.045 1.65
Oxygen 0.042
TDO Tryptophan 0.222 1.4 [16]
Oxygen 0.037
AFMID N-formylkynurenine 0.05 100 [17, 18]
KAT I l‐kynurenine 4.7 3.35 [19]
KAT II l‐kynurenine 4.7 9.76 [20]
3-hydroxykynurenine 3.8 1.7
KAT III l‐kynurenine 1.5 2.3 [21]
KMO l‐kynurenine 0.89 1.88 [22]
Oxygen 0.071
NADPH 0.82
KYNU l‐kynurenine 0.495 0.23 [23]
3-hydroxykynurenine 0.028 3.5
3HAADO 3-hydroxyanthranilic 
acid
0.016 64 [24]
Oxygen 0.615
ACMSD 2-amino-3-carboxy 
muconate semialdehyde
0.0065 1 [25]
QPRT Quinolinic acid 0.022 0.05 [26]
Table 1. Enzyme kinetics parameters for the kynurenine pathway enzymes.
Mechanisms of Neuroinflammation266
2. Role of kynurenine pathway in brain
Although NAD+ is a final product of the KP, many of the intermediary metabolites, the so-
called kynurenines, have demonstrated to exert many effects on cellular homeostasis and 
bioenergetics resulting on changes in organism behavior or immune response. In brain, Trp 
is transported through the blood‐brain barrier by the large neutral amino acids transporter 
[27]. The imbalance on the levels of its metabolites (kynurenines) has been related with the 
progression of neurodegenerative disorders, such as Huntington, Alzheimer, and Parkinson 
due to their redox nature and their capacity to exert neuromodulatory mechanisms [28].
On a redox perspective, both 3-HK and 3-HAA represent a double-edged sword. Reports show 
that 3-HK is able to promote cell death due to the increase in reactive oxygen species (ROS) 
production; also, 3-HK interaction with metallic ions promotes protein aggregation as well as 
cataract formation and toxicity in neuronal cultures without region selectivity [29–32] point‐
ing this kynurenine as a pro-oxidant and cytotoxic compound. In the same way, 3-HAA is 
able to cause protein damage due to interaction with metals producing OH•; furthermore, this 
metabolite causes oxidative phosphorylation uncoupling and decreased oxygen consumption 
[31, 33]. On the other hand, there are reports pointing to the antioxidant and protective side of 
these molecules, demonstrating a 3-HK-induced decrease of oxidative stress parameters; also, 
it has been observed that 3-HK acts as a free radical scavenger of radicals like O2•− [34, 35]; the antioxidant activity of 3-HAA also has been reported showing free radical scavenging and 
ROS production decrease [36]. Finally, the protective effect of 3-HK and 3-HAA on the inhib‐
ited mitochondrial electron transport chain, as electron carriers, also has been reported [37].
On the other hand, Kyna is the only endogenous antagonist to N-methyl-d-aspartate (NMDA) 
receptors known so far, it inhibits the α7-nicotinic receptors, showing anticonvulsant effects 
on murine models as well as in human patients [38]. Recently, it was found that Kyna is a free 
radical scavenger of radicals, such as superoxide anion (O2•−), hydroxyl radical (OH•), and peroxynitrite (ONOO−), besides it is able to reduce oxidative damage caused by pro-oxidants, 
so it is considered an endogenous antioxidant [39]. Furthermore, it has been shown that Kyna 
binds selectively to GPR35 receptor [40]; Kyna-mediated activation of GPR35 leads to intracel‐
lular Ca2+ influx, inositol phosphate production and, attenuates LPS-induced TNF-α release 
and reduces acetic acid-induced pain, suggesting that GPR35 could be mediating Kyna excit‐
atory, anti-inflammatory, and antinociceptive functions [40–42]. Contributing with the anti-
inflammatory response, Kyna also has been described as an agonist of the intracellular aryl 
hydrocarbon receptor (AHR); AHR translocation into the nucleus modulates the production 
of proinflammatory mediators and, as discussed below, inhibits T immune responses [43]. 
Because of Kyna is unable to cross the blood-brain barrier, systemic l‐kyn administration has 
been used to show the protective effect of Kyna in 6-hydroxidopamine-induced Parkinson 
disease models, hippocampal β-amyloid, and glutamate toxicity [44–46].
Contrasting with Kyna, Quin has been described as an agonist of NMDA receptors; in fact, 
it has been demonstrated that Quin is a pro-convulsive agent which generates mitochon‐
drial progressive dysfunction by reducing activity of respiratory complexes II and III [47], 
increases ROS production and lipid peroxidation in presence of Fe2+ [48], induces Ca2+ cel‐
lular influx increase, release of glutamate, and apoptosis [49–51]. Recently, the decrease in 
Role of Kynurenine Pathway in Glioblastoma
http://dx.doi.org/10.5772/intechopen.68939
267
autophagy inhibition by Beclin-1 reported in human astrocytes and neurons has been attrib‐
uted to Quin toxicity [52]. Because of the selective damage that exerts in striatal spiny neurons 
with γ-amino butyric acid and substance P, Quin has also been a good model to mimic early 
symptoms of Huntington's disease [53–55]. In addition, increases in Quin concentrations were 
observed in the cerebral cortex of macaques infected with retroviruses, particularly those with 
local inflammatory lesions [56]. Moreover, Quin levels are increased in cerebrospinal fluid in 
the acquired immunodeficiency syndrome and in HIV patients; also in humans, Quin levels 
are elevated after traumatic brain injury [57].
2.1. Inflammatory process and kynurenine pathway components
Moreover, kynurenine pathway has been related to inflammatory processes. It has been 
shown that IDO, KMO, and KYNU expression is strongly induced by proinflammatory cyto‐
kines, mainly interferon‐ɣ (IFN-ɣ), interleukin 1 (IL1), interleukin 17 (IL17), or the tumor 
necrosis factor α (TNF-α) during bacterial and viral infections in immune privileged tissues, 
such as brain [58, 59]. Thus, activation of the KP by proinflammatory molecules inhibits bacte‐
rial proliferation through tryptophan depletion, avoids autoimmune responses by limiting T 
cell activation and recruiting of immune regulatory cells [60–62]. The immunoregulatory role 
of the KP could act as a double-edged sword, meanwhile it is inhibiting pathogen growth and 
regulating immune responses to avoid an autoimmune damage, the same activation during 
cancer supports tumor immune evasion and promotes tumor growth and invasiveness.
Beyond their role on neurodegenerative disorders, kynurenines have also been related with 
cancer progression in more than one way. It has been described that IDO expression is high in 
all thyroid carcinomas [63]. Moreover, l-kyn and Quin promote neoplastic cell proliferation 
in vitro and the formation of larger tumors in vivo, in a colorectal cancer model, through the 
Wnt/β-catenin signaling, despite of the ablation of IDO [64]. l‐kyn modulates the repairing 
enzyme DNA polymerase kappa, protecting tumor cells from DNA damage and propitiating 
genomic instability [65]. Also, Quin produced by microglial cells in glioma models confers 
tumor tolerance to oxidative stress due to the production of NAD+, promotes cell prolifera‐
tion by the modulation of the fibroblast growth factor-1 (FGF-1) release, and it is elevated in 
children with central nervous system tumors [66–68]. Kyna also promotes glioma cell prolif‐
eration through FGF-1 release [67]. The high expression and activity of the KP in the tumor 
microenvironment will be reflected on the maintenance of the NAD+/NADH supply, NAD+ 
and its reduced form NADH participate in several metabolic, redox, and stress response 
signals, providing favorable growing conditions for cancer cells. Finally, IDO expression 
and activity as well as the kynurenines promote cancer development by affecting the host's 
immune responsiveness. The effects of the KP on cancer immunosuppressive mechanisms 
will be detailed below.
2.2. Cancer immunoedition
All the cancer cells must possess a series of characters that allow them to develop tumors, these 
“hallmarks” let cancer cells to rapidly grow, evade cell death, migrate through the organism and 
colonize new tissues, modify their metabolic program, and to avoid immune destruction [69].
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Before the establishment and development of a tumor, cancer cells must overcome elements 
of the immune system of the organism that can recognize, induce cellular signals, and finally, 
destroy exogenous agents or defective cells within the organism. In the early twentieth century, 
Paul Ehrlich formulated the idea that the immune system of an organism is able to recognize, 
destroy, and then protect against tumor cells. Later in the mid-twentieth century, the “immu‐
nosurveillance” hypothesis was then postulated by Sir Macfarlane Burnet and Lewis Thomas, 
based on this original idea and in experimental evidence of that, mouse lacking of interferon-γ 
responsiveness or with adaptive immunity defects, were susceptible to develop cancer [69, 70]. 
More recent evidence has demonstrated that the immune system not only protects against can‐
cer progression, immune cells, and signaling but also promotes tumor cell establishment, and 
furthermore, cancer cells modulate immune mechanisms favoring tumor progression, trans‐
forming the idea of “immunosurveillance” into the “cancer immunoediting” hypothesis [69–70].
The cancer immunoediting hypothesis postulates that cancer cells and immune system cre‐
ate a set of dynamical interactions during the formation of a tumor; these interactions are 
arranged in three stages of the “cancer immunoediting,” or “The three E's hypothesis” pro‐
cess named: elimination, equilibrium, and escape [70]. During the elimination phase, cancer 
cells are recognized by the immune system and cytotoxic reactions induce cancer cell death; 
in the equilibrium phase, the cytotoxic mechanisms of the immune system act as selective 
pressure on tumor cells; cancer cells that survive, remain proliferating and establishing the 
tumor. Finally, at the escape phase, cancer cells are able to evade and suppress the immune 
mechanisms leading to the formation of tumors [70–72].
Cancer immunoediting mechanisms could be given by genetic alterations, proper of the can‐
cer cells, which induce overexpression and secretion of suppressive molecules, such as the 
transforming growth factor-β, the vascular endothelial growth factor, prostaglandin E2, and 
the soluble MHCI-related gene A; cancer cells also recruit immune regulatory cells like T regu‐
latory cells (Tregs), myeloid-derived suppressor cells (MDSC), and tolerogenic dendritic cells 
(TDC); and finally, by induction of immune checkpoint, inhibitory molecules, such as PD-L1 
[73]. A second type of immunoediting is carried out by cytotoxic T cells of the own adaptive 
immune system, while exerting their protective role against cancer, T cells release cytokines 
like IFN-γ which can also induce the production of immune suppressive molecules by tumor 
cells, during the equilibrium phase of the “cancer immunoediting” [73]. Remarkably, IFN-γ is 
a strong inducer of IDO expression and activity which leads tryptophan metabolism through 
the KP in tumor microenvironment, and then to the triggering of the kynurenines’ immuno‐
suppressive effects [73, 74]. In cultured human glioma, stimulation with IFN-γ significantly 
increased the expression of IDO-1, IDO-2, kynureninase, and kynurenine hydroxylase, which 
potentiate the KP; whereas significantly decreased 2-amino-3-carboxymuconate semialde‐
hyde decarboxylase (ACMSD) and kynurenine aminotransferase-I (KAT-I), which reduce the 
neuroprotective metabolites [75].
2.2.1. The kynurenines in cancer immunoediting
As mentioned above, the own immune response against tumors could propitiate the forma‐
tion of an immunosuppressive microenvironment, one of these mechanisms is carried out 
Role of Kynurenine Pathway in Glioblastoma
http://dx.doi.org/10.5772/intechopen.68939
269
by IFN-γ and other proinflammatory cytokines secreted by cytotoxic lymphocytes which 
strongly induce IDO expression. Beyond the increase of IDO levels in tumor cells, the forma‐
tion and accumulation of different kynurenines have demonstrated immunosuppressive and 
immunoinhibitory effects [76].
Recent works have demonstrated that tryptophan starvation is able to inhibit T cell and mac‐
rophage cell viability and proliferation [77–80]. Furthermore, KP metabolites have also shown 
direct effects as immunosuppressive molecules. l-kyn is able to activate the aryl hydrocarbon 
receptor (AHR) and thus to promote the generation of Tregs from naive T cells [81]. Moreover, 
there are reports showing that 3-HAA, 3-HK, and Quin promote Treg generation and that 
3-HAA and 3-HK block T cell activation and induce cell death of CD4+ T and CD8+ T cells as 
well as of natural killer cells (NK) and B lymphocytes [82–86]. All these reports settle down 
the idea that immunosuppressive mechanisms carried out through the KP activation may 
be due to tryptophan deprivation of the tumor microenvironment or secondly, by the direct 
effect of the kynurenines on Treg recruitment and the impact on viability of effector T cells. 
Finally, both tryptophan depletion and the presence of the KP intermediates could enhance 
an immunosuppressive environment. It has been showed that l-kyn, Pic, 3-HK, 3-HAA, and 
Quin reduced cell viability and induced apoptosis on CD4+ in absence of tryptophan [82, 83]; 
besides at lower concentrations were able to increase Treg-mediated immunotolerance [84].
It is relevant to note that in some cases, the kynurenines are not produced by cancer cells but by 
other components of the tumor microenvironment, such as dendritic cells (DCs) or mesenchymal 
stem cells and also by microglial cells in the case of brain tumors [83, 87, 88]. Regarding dendritic 
cells expressing IDO, they can suppress effective immune responses through diverse strategies: 
by inhibiting the proliferation and effector functions of cytotoxic cells, such as NK and CD8+ T 
lymphocytes, as well as plasma cells; by inducing of CD4+ CD25+ FOXP3+ regulatory T cells 
from naive CD4+ cells; and by triggering immunosuppressive activity in adjacent IDO-express‐
ing DCs [89]. Possible implication of IDO2 in cancer immunosuppression has been suggested 
due to reports showing its ability to mobilize the nuclear factor interleukin 6 inhibitor, LIP [6].
Thus, locating the IDO expression and the kynurenines in the “Three E's” context, it would be 
in this way: IFNɣ, TNFɑ, and proinflammatory cytokines secreted by cytotoxic lymphocytes, 
while killing recognized tumor cells during Elimination and Equilibrium phases, induce IDO 
expression of tumor cells, those that survived to immune response, and of other infiltrating 
cells, such as DCs and macrophages. Tumor cells expressing IDO, deplete tryptophan from the 
tumor microenvironment and begin to produce kynurenines and NAD+; tryptophan depletion 
from, and release of kynurenines to the tumor microenvironment, inhibit T cells and NK prolif‐
eration; induce apoptosis, while promote differentiation and proliferation of Tregs, and recruit‐
ing of DCs and macrophages. NAD+ production allows cancer cells to overcome DNA damage 
and oxidative stresses, promoving their proliferation during the Escape phase.
Because of the importance of the KP in brain and the relationship of tryptophan catabolism 
with immune modulation during cancer, researchers have begun to clarify the role of the acti‐
vation of this pathway on glioblastoma progression for further development of new strategies 
to treat this illness.
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2.3. The glioblastoma multiforme
Astrocytes are non-excitable nervous cells of great importance for the physiological maintenance 
that exert on neurons, by regulating ions and excitatory amino‐acids concentrations on synaptic 
regions, forming the brain-blood-barrier (BBB)-mediating neuron-blood stream signaling and 
regulating the transport of nutrients into and out of the brain [90, 91]. Beyond this, astrocytes can 
be differentiated on a wide span of morphological, physiological, and genomic subtypes [90–91].
Deregulation of cell proliferation and uncontrolled proliferation caused by mutations of cer‐
tain genes lead astrocytes to transform into astrocytomas. Astrocytomas have been classified 
into four subtypes depending on the rate of proliferation and the grade of malignancy: grade 
I pilocytic astrocytomas are non-invasive tumors, they represent the less malignant of astrocy‐
tomas; diffuse astrocytomas are grade II tumors that tend to invade peripheral tissues but their 
growth rate is slow; anaplastic astrocytomas grow faster than diffuse astrocytomas and tend 
to form tentacle-like projections into surrounding tissues, instead of grade III anaplastic astro‐
cytomas, their frequency is low; finally, glioblastomas (GBM), also known as glioblastoma 
multiforme, are grade IV tumors, these are the most malignant of astrocytomas [92]. GBM 
can be originated de novo from mature astrocytes, primary GBM, or from a less malignant 
astrocytoma, secondary GBM; they represent 15.1% of all brain primary tumors and 55.1% of 
all gliomas [93].
Incidence rate of GBM is 3.19 per 100,000 people with a median age at diagnosis of 64 years 
old for primary GBM, and 45 years old for secondary GBM, the median survival overall for 
diagnosed and treated GBM ranges between 12 and 14 months [94, 95]. Furthermore, GBM 
represent 2.8% of brain tumors during childhood [96]; however, its frequency is lower in 
adults, high-grade astrocytic tumor incidence rate is 0.85 per 100,000 people being more fre‐
quent in children between 5 and 9 years old, also, the median survival overall is over 43 
months [97–99]. The most common treatment for GBM is surgical resection of the tumor, 
followed by temozolomide-based chemotherapy, and 5000–6000 Gy radiotherapy which pro‐
longs the lifespan 202 weeks [100–102]. Despite the treatment, the survival of afflicted patients 
is no longer than 14 months and only 5% of the patients have a survival rate of 5 years. It is 
believed that the lack of response of GBM to the multimodal treatment is due to multiple fac‐
tors that combined, make GBM resistance and aggressiveness.
A major character among GBM is a loss-of-function mutation of Retinoblastoma (Rb) gene, 
a cell cycle regulator protein at the phase G to phase S checkpoint, that also regulates apop‐
tosis and differentiation, which occurs on 77% of GBM [103, 104]. Instead of that, another 
genetic mutations and genomic expression patterns differ among GBM, integrated genomic 
analysis originated four types of GBM named: proneural, associated with PDGFRA, IDH1, 
and TP53 mutations; neural, expressing neuronal markers, such as NEFL, GABRA1, SYT1, 
and SLC12A5; classical, showing amplifications on EGFR expression and deletions of Ink4a/
ARF locus; and mesenchymal, characterized by overexpression of CHI3L1 and MET so as 
deletion of NF1 [103]. Several other mutations in key oncogenic signaling pathways, such as 
the receptor tyrosine kinase (RTK)/RAS/PI3K, p53 pathways, lead to uncontrolled tumor cell 
proliferation, genomic instability, and resistance to therapeutic strategies.
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GBM may have a wide cellular diversity, more than tumor cells which are polygonal or spindled 
small sized with big nuclei, GBM-initiating cells (also called glioma stem cells) are responsible 
for cell proliferation and renewal of GBM cells, also confer chemo- and radioresistance; infiltrat‐
ing multinucleated cells, such as lymphocytes, macrophages, and neutrophils, and cells with 
lipid vacuoles are present in these tumors [105]. Because GBM are highly angiogenic tumors, 
blood vessels surrounded by pericytes are also present in tumors. GBM also show necrotic 
regions among the central body tumor and some other necrotic foci in outer regions of the tumor 
[105, 106]. In addition to all these mechanisms, the GBM has the ability to create an immuno‐
suppressive environment that prevents the response lead by the immune system against GBM.
2.3.1. Immunosuppressive environment in GBM
Historically, the brain has been considered an immune privileged organ due to the inability 
of reject exo-grafts and the lack of response in case of infection [107], as well as, absence of 
a normal response of the lymphatic system and the extremely distinctiveness of antigen-
presenting cells (APCs) in brain tissue [108, 109]. However, diverse studies have recently 
found that there is not an absolute isolation of the rest of the organism; moreover, within 
the dural sinuses is located a lymphatic system that connect with the deep cervical lymph 
nodes, able of taking immune cells and macromolecules into the CNS [108].
Even with this lymphatic system, the access to CNS is highly regulated, mostly by the BBB 
[110]. The BBB is a highly selective layer composed of basement membranes, brain pericytes, 
astrocytes, and neurons, which have the ability to reject more than the 90% of small molecules, 
allowing the entrance just to certain lipophilic molecules [111]. However, it has been observed 
that when a GBM appears, this tumor easily disrupts the BBB due to this abnormal structure, 
which has as consequence the free-crossing of a more varied group of substances into the CNS 
[111] and also cells of the immune system.
GBM is infiltrated by several cell types, such as monocyte-derived cells, microglia, and activated 
T cells. These immune cells are recruited by chemotaxis to the tumor and together with molecules 
secreted by GBM itself, such as IL-10, prostaglandins, and TGF-β1 (Table 2), playing a major role 
in the immunosuppression of the tumor [112–113]. Specifically, several studies have found that 
the infiltration of T cells subtypes is higher in GBM than any other CNS tumor [114], comprising 
between 10 and 30% of cells within the tumor mass [115–116]. Due to the production of immu‐
nosuppressive cytokines, inhibition of T cell proliferation, activation of Tregs and hypoxia, an 
immunosuppressive environment, is made in GBM, which can be enhanced by the activation of 
the KP.
Because of the high immunosuppressive conditions in the GBM, new therapies have begun 
to being developed, focusing on antitumoral immune response for improvement of GBM 
patients. Thus, epidermal growth factor receptor (EGFR) variant III-specific peptide vaccina‐
tion and autologous tumor lysate-DC vaccination have been tested with successful results on 
phase I and phase II clinical trials [117–120]. However, a better understanding of the immuno‐
suppressive mechanisms occurring during GBM development, including those carried out by 
IDO activity and the kynurenines, could impulse the furtherance of new tools and strategies for 
GBM treatment.
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2.3.2. Implications of kynurenine pathway in GBM development
Kynurenine pathway enzymes are overexpressed in GBM. Upregulated expression of these 
enzymes has been related to severity of gliomas and patient survival. The IDO expression in 343 
glioma specimens and correlated to patient survival has been analyzed [134], this expression 
was associated with poor prognosis and was more frequently observed in high-grade glioma. 
Moreover, in an orthotopic GL261 cell tumor model was shown that IDO-competent brain 
tumors increased the recruitment of immunosuppressive Tregs, and decreased the frequency 
of CD8+ T cells compared with IDO-deficient brain tumors [134]. Another study, including 75 
gliomas, showed higher expression of IDO in malignant gliomas compared with low-grade 
gliomas. Moreover, stronger IDO expression was associated with shortened survival time in 
GBM patients [135]. Additionally, it has been reported that glioma cells have increased mRNA 
Molecule Effect Mechanism
Interleukin-10 (IL-10) Induce apoptosis in T cells, possibly 
through the expression of Fas-ligand
[121–123]
Tumor-promoting cytokines Dampen the antitumor immune  
response
[124, 125]
Interleukin-6 (IL-6) Shifting adaptive immunity to  
humoral response (TH2)
[124, 126]
Prostaglandin E2 (PGE2) Dampen the antitumor immune  
response suppressing lymphocyte 
proliferation
[124, 125, 127–129]
TGF-β1 Ability to polarize TAMs toward  
M2 phenotype
CD70 and ganglioside Promotion of T cells apoptosis [130, 131]
Colony stimulating factor-1 (CSF-1) Stimulating of monocytic cells [124, 126]
Ability to polarize TAMs toward  
M2 phenotype
Basic fibroblast growth factor (BFGF), Dampen the antitumor immune  
response
[124, 125]
Vascular endothelial growth factor 
(VEGF)
Proangiogenic factor. [132]
Support of vascularity and tumor  
growth
Factor-1α (HIF-1α) Activation of Tregs and production 
of vascular endothelial growth factor 
(VEGF)
[133]
Transcription 3 (STAT3) Synthesis of hypoxia-inducible factor 
-1α (HIF-1α) that subsequently  
induces activation of Tregs and 
production of vascular endothelial 
growth factor (VEGF).
[133]
Promotion of angiogenesis
Table 2. Molecules implicated in the immunosuppression of GBM.
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expression of IDO1 and IDO2 compared with human fetal astrocytes and human adult astro‐
cytes cultures as well as decreased Kats mRNA expression, and these expression enhanced 
when cells were stimulated with IFNɣ [75]; the same work also reported increased Kyn/Trp 
ratios and decreased Kyna/Kyn ratios in the plasma of glioblastoma patients compared with 
healthy people [75]. The levels of Trp and Kyn were evaluated in GBM patients before and 
after tumor resection. Interestingly, both Trp and Kyn significantly decreased after 48 h and 10 
weeks after surgery. In addition, patients with a high-ratio Kyn/Trp had worse mean overall 
survival compared with patients with lower ratio [136].
The significantly increased expression of IDO in cancer cells and in the tumor microenviron‐
ment has arisen as a promising target for GBM treatment, based on the inhibition of IDO as 
a potential therapy for cancer patients. Among the first strategies, is the systemic adminis‐
tration of 1-methyl tryptophan (1-MT), a competitive inhibitor of the IDO, which delayed 
tumor development in a murine model of Lewis lung carcinoma [137]. Subsequently, it was 
described that the expression of IDO in immunogenic cells (P815B) avoided their rejection 
by preimmunized mice, an effect that was associated with the inhibition of specific T cell 
response [138]. This effect was partially reversed when preimmunized mice were adminis‐
tered with 1-MT [138]. Due to the results observed in animal models, 1-MT has been tested 
and approved on phase I clinical trials in patients with solid and solid metastatic neoplasms, 
lung, ovarian, Fallopian tube, and breast cancer showing disease stabilization in most cases 
[89, 139–141].
Concerning to GBM, at least three clinical trials involving IDO inhibitors are in recruiting status 
(Feb. 2017), but the use of 1-MT on in vivo GBM models has shown that when is used in com‐
bination with classical chemotherapeutic agents, such as temozolomide or cyclophosphamide, 
and additional radiotherapy, increases the overall survival as well as reduces the tumor volume 
[142, 143]. Additionally to this effect, inhibition of IDO has also shown increased complement 
component C3 deposition on the tumor region, which is necessary for tumor volume reduction 
[142], as well as increased CD4+ and CD8+ T cell population from animal spleens, treated with 
1-MT [143], indicating that IDO inhibition rescues the host’s immune activation.
Despite reports pointing that 1-MT has a greater affinity for IDO2 than for IDO [6, 7], it is of 
mention that the majority of reports about the targeting of the KP for cancer treatment are 
focused on IDO inhibition. But IDO is just one of the enzymes that fuel this catabolic route, 
so the better understanding of the roles of both IDO2 and TDO in cancer development and 
immunosuppression would result in better ways for combating cancer [144].
As mentioned above, in most cases, IDO expression as well as kynurenines production and 
immunosuppressive mechanisms are carried out by infiltrating tumor cells. For GBM, microg‐
lial cells are an important source of kynurenines so, the microglial depletion could be another 
important strategy for tumor mitigation. Studies focusing in microglial depletion through the 
use of CSF-1 receptor inhibitors have shown prolonged mice survival and enhanced antitu‐
moral immune response when animals were treated in combination with DC vaccination [145, 
146]. The effect of microglial elimination on IDO expression and on the levels of KP metabo‐
lites, still remains to be elucidated, but the immune response reported with the use of the 
CSF-1 receptor inhibitors settle down some clues about what could happen in the KP context.
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Thus, the use of IDO inhibitors and microglial elimination in combination with classical che‐
motherapy and radiotherapy in GBM murine models, as well as the clinical trials that have 
tested 1-MT in different kinds of solid and metastatic tumors has shown promising results for 
targeting IDO and the KP against GBM.
2.4. Concluding remarks
GBM is an astrocyte-derived tumor, the most common of brain tumors, characterized by its 
high proliferation rates, genomic instability, and invasiveness, as well as to being a high immu‐
nosuppressive tumor. The nature of GBM results in a rapid expansion into the surrounding 
tissues, associated with poor prognosis and patient low survival despite classical treatment of 
these tumors, tumor extirpation, temozolomide therapy, and radiotherapy, which only pro‐
longs median survival over 2 months.
In this chapter, we have discussed the importance of the tryptophan catabolism through the KP 
during GBM development. Activation of this catabolic route provides cancer cells a constant 
Figure 3. Global scheme of the role of IDO expression and the kynurenine pathway on glioblastoma development. 
During glioblastoma formation, a population of tumor cells is recognized and eliminated by the host immune system 
(cytotoxic T lymphocytes, helper T lymphocytes, and natural killer cells). While eliminating the recognized tumor 
cells, cytotoxic T lymphocytes secrete IF Ny, TNFα, and other proinflammatory cytokines which strongly induce IDO 
expression and the kynurenine pathway activation in survivor glioblastoma cells and tumor infiltrating cells (dendritic 
cells and tumor-associated macrophages). Glioblastoma IDO expressing cells maintain a rich NAD+/NADH pool which 
provides redox balance, energy supply, and active DNA repairing mechanisms, facilitating genomic instability and tumor 
growth; also in glioblastoma cells, l-kyn also contributes to genomic instability by modulating DNA polymerase κ. In 
the tumor microenvironment, released l-kyn promotes Treg differentiation from naïve T cells. While 3-HAA, 3-HK, 
and Quin promote Treg recruitment and inhibit both cytotoxic and helper T lymphocytes activation and proliferation; 
and also promote T lymphocytes, natural killer cells, and nontumor cells apoptosis, promoting more invasiveness. 
Microenvironmental tryptophan depletion caused by high tryptophan uptake by IDO expressing cells enhances the 
kynurenines effect against T cell activation proliferation. Finally, the use of IDO inhibitor 1-methyl-tryptophan rises as a 
promising strategy for glioblastoma treatment.
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supply of NAD+ and promotes the expression of damaged DNA repairing enzymes, which 
allow cancer cells to have an active metabolism, and to bypass redox stress and DNA damage 
pressure (Figure 3).
Furthermore, IDO expression and elevated Kyn/Trp ratios are related with poor prognosis 
and low survival of GBM patients. The expression of key enzymes of the KP is induced by 
stimulation of cytokines secreted during antitumoral immune responses, after this, trypto‐
phan depletion and kynurenines production inhibit effector CD4+ and CD8+ T cell and NK cell 
proliferation, meanwhile promote Treg differentiation and MDSC infiltration into the tumor, 
attenuating antitumor responses. It is of note that IDO expression and immunosuppressive 
mechanisms are not carried out by cancer cells alone, but tumor infiltrating cells are also able 
to synthesize IDO and to promote an immunosuppressive environment (Figure 3).
The results of the use of IDO inhibitors, like 1-MT, in in vivo GBM models and in phase I and 
phase II clinical trials against lung, breast, and ovarian cancer, arise them as a promising strat‐
egy for combating GBM. However, detailed information about the role of key enzymes of the 
KP, KYNU, KAT, KMO, and QPRT, could provide more information for the development of 
more truthful treatments against GBM.
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